1. Home
  2. SILC vs CNTN Comparison

SILC vs CNTN Comparison

Compare SILC & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silicom Ltd

SILC

Silicom Ltd

HOLD

Current Price

$41.34

Market Cap

163.8M

Sector

Technology

ML Signal

HOLD

CNTN

Canton Strategic Holdings Inc. Common Stock

N/A

Current Price

$3.11

Market Cap

185.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SILC
CNTN
Founded
1987
2017
Country
Israel
United States
Employees
N/A
12
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
163.8M
185.3M
IPO Year
2002
2022

Fundamental Metrics

Financial Performance
Metric
SILC
CNTN
Price
$41.34
$3.11
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
180.2K
461.0K
Earning Date
04-30-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.17
N/A
Revenue Next Year
$12.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.34
$2.89
52 Week High
$52.58
$5.27

Technical Indicators

Market Signals
Indicator
SILC
CNTN
Relative Strength Index (RSI) 50.69 42.96
Support Level $40.00 $3.04
Resistance Level $50.75 $3.82
Average True Range (ATR) 4.20 0.27
MACD -0.99 -0.01
Stochastic Oscillator 5.15 10.39

Price Performance

Historical Comparison
SILC
CNTN

About SILC Silicom Ltd

Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

Share on Social Networks: